Sanuwave lowers Q2 2026 guidance to $8.5-$9.5M due to market disruption
Sanuwave Health reduced its Q2 2026 revenue guidance below prior expectations due to CMS reimbursement clawbacks forcing wound care practices to close and flood the market with used Ultramist systems. While consumable applicator volumes remain robust, capital equipment sales face
View filing at SEC.gov →